BioCryst Pharmaceuticals, Inc.
- BCRX
- NASDAQ
- Biotechnology
- Influenza Treatment
- Hereditary Angioedema
- Oral Small-Molecule Drugs
$8.07
Today +3.59%Quote Oct 19, 2026, 08:00 PM UTC
−10.46%over the last month
Max drawdown −11.3%From 1-month high −11.3%3 months −14.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza.
Where the money comes from
Q2 2026 revenue $218.3M
- Product$157.5M72.2%
- License and Other Revenues$60.7M27.8%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
435
Market value
$2.06B
Quote Oct 19
Floor
$7.87
2.5% below price
Resistance
$8.05
Price is above this level
Price vs analyst targets
29 analysts
Lowest target
$11.00Highest target
$29.00
$11.00Highest target
$29.00
- Price $8.07
- Average target $19.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 135% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BCRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free